12th Antibody Industrial Symposium 2024 June 20 - 21 2024 | Montpellier - France


schedule & speakers

Day 1

Thursday, June 20th 2024


Registration and welcome coffee


Welcome Address - Einstein Auditorium



Next generation bispecific antibodies and antibody fusion proteins for cancer immunotherapy
Roche Christian Klein

Christian Klein
Distinguished Scientist, is Department Head Cancer Immunotherapy Discovery 3, Head Oncology Programs & Site Head Roche Innovation Center Zurich
Roche pRED, Switzerland

Clinical development of bispecific antibodies and ADCs: toxicity mitigation and activity optimization strategies in expanded phase I trials
The Sarah Cannon Research Institute Elisa Fontana

Elisa Fontana
MD, PhD, Hospital Medical Director
The Sarah Cannon Research Institute in London, UK


Coffee Break at Exhibition Hall


Paving the way for the next-generation of Antibodies & New Modalities - Einstein Auditorium

Session I

KnotBodies: creating Ion Channel Modulating Antibodies by fusing Knottins in Antibody loops
Maxion Therapeutics John McCafferty

John McCafferty
Maxion Therapeutics, UK

Title to be announced
CellmAbs Paula Videira

Paula Videira
Associate Professor
NOVA School of Science & Technology, Univ. NOVA de Lisboa, Portugal

Engineering and characterization of ImmTAC
Immunocore Peter Molloy

Peter Molloy
Senior Fellow, Protein Engineering
Immunocore Ltd, UK

Antibody-based Cancer Therapies : latest developments - Barthez Auditorium

Bispecific Antibody Drug Conjugates (BsADCs): strategies and challenges
Pierre Fabre Alain Beck

Alain Beck
Senior Director, Biologics CMC & developability
Pierre Fabre, France

Innovative cancer therapies based on first-in-class antibodies anti-GPCR drug conjugates
Skymab Biotherapeutics Aiphi Andrée Nguyen

Aiphi Andrée Nguyen
Skymab Biotherapeutics, France

Title to be announced
Merus Peter Lowe

Peter Lowe
Director Antibody Engineering
Merus, Netherlands


Lunch at Exhibition Hall


Paving the way for the next-generation of Antibodies & New Modalities - Einstein Auditorium

Session II

Exploiting the advances of soloMER biologics to deliver multi-functional products for autoimmune diseases and cancer
Elasmogen Caroline Barelle

Caroline Barelle
CEO & founder
Elasmogen, UK

De novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization
Merck Healthcare KGaA Stefan Zielonka

Stefan Zielonka
Global Head of Antibody Discovery & Protein Engineering
Merck Healthcare KGaA
Professor of Biomolecular Immunotherapy
Technical University of Darmstadt, Germany

Discovery and Development on Non-IgG based antibodies treatments - Barthez Auditorium

Avidity Engineering : a next frontier in the development of differentiating antibody therapeutics
GYES Simone Oostindie

Simone Oostindie
Director Research & Discovery
GYES, Netherlands

Streamlining Therapeutic Antibody Development with Lumit Cellular Immunoassay/Streamlining Therapeutic Antibody Development with a Homogeneous Bioluminescent Immunoassay for Signaling Pathway Analysis
Promega Hicham Zegzouti

Hicham Zegzouti
Senior Research Scientist - Group Leader
Promega, USA


Pitch Session : Innovative Approaches and New trend Technologies - Einstein Auditorium

Call for abstracts until April 12th, 2024


Round table - Enhancing Investment Understanding - Einstein Auditorium


Investor's Pitch - Einstein Auditorium

(Panel added soon)

Apply until May 12th, 2024


Poster Presentation - Dinner Cocktail Reception at Exhibition Hall


End of DAY 1

Day 2

Friday, June 21st 2024


Welcome coffee


Efficacity and safety from preclinical to FIH trials - Einstein Auditorium

Session I

Pharmacokinetics strategies to First in Human for different biotherapy modalities
SANOFI Antoine Deslandes

Antoine Deslandes
Global Head of Pharmacokinetics for Devices & Biotherapeutics
SANOFI, France

From preclinical to clinical: PK-PD modelling of an antibody drug conjugate for therapeutic index prediction
Pierre Fabre Laurence del Frari

Laurence del Frari
Pharmacokineticist, Modeling & Simulation
Pierre Fabre, France

Feasibility Assessment in Therapeutic Antibody Development: Leveraging PK/PD Modeling to Navigate Challenges and Mitigate Pitfalls
Lyo-X Lionel Renaud

Lionel Renaud
PK/PD and Systems Pharmacology modeler
Lyo-X, Switzerland

Non-oncology diseases/next generation of immunotherapies - Barthez Auditorium

bNAbs and immunotherapy in HIV curative strategies
Institut for Klinisk Medicin, Aarhus University Ole Søgaard

Ole Søgaard
Institut for Klinisk Medicin, Aarhus University, Denmark

Multimeric complexes to unlock the therapeutic potential of innate immunity
Luxemburg Institut of Health Carole Seguin Devaux

Carole Seguin-Devaux
Head of Research Unit
Luxemburg Institut of Health, Luxemburg

Immunotherapy for SARS-CoV2 infections
IRMB-INSERM U1183-CHU Saint Eloi, France Mireia Pelegrin

Mireia Pelegrin
DR-CNRS, Head of Antibodies, Immunomodulation and Immunotherpay group
IRMB-INSERM U1183-CHU Saint Eloi, France


Coffee Break at Exhibition Hall


Efficacity and safety from preclinical to FIH trials - Einstein Auditorium

Session II

AI and Machine Learning for Antibody discovery, Optimization and Clinical development - Barthez Auditorium


Speakers to be announced soon


Lunch at Exhibition Hall


Advancing new Antibodies approaches into the Clinic - Einstein Auditorium

First-in-Class anti-ChemR23 pro-resolutive agonist mAbs triggers the Resolution of chronic Inflammation
Ose Immunotherapeutics Nicolas Poirier

Nicolas Poirier
Ose Immunotherapeutics, France

Next-generation bispecific T cell engagers with built-in autoregulation to prevent treatment-related adverse events in adoptive T cell immunotherapies
NovalGen Vincent Muczynski

Vincent Muczynski
Director of Biology
NovalGen Ltd
Research Fellow
University College London - Cancer Institut, UK

Innovative Approaches to overcome Bioprocessing Challenges - Barthez Auditorium

Innovations in DSP and new trends
SANOFI Benoit Mothes

Benoit Mothes
Head of Purification Process Development
SANOFI, France


Closing Keynote - Einstein Auditorium

Title to be announced
Institute for Research in Biomedicine Luca Varani

Luca Varani
Structural Biology Group Leader
Institute for Research in Biomedicine, Switzerland


Best Poster- Announcement of AIS2025


End of Congress

Organization contact
Ana Antunes
17 rue Crépet
69007 Lyon
+33 (0)6 26 33 63 21